A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men.
Several preparations of testosterone and its esters are being investigated alone or in combination with other gonadotropin-suppressing agents as possible antifertility agents for men. We studied the effectiveness of 7 alpha-methyl-19-nortestosterone (MENT) as an antispermatogenic agent in men. MENT has been shown to be more potent than testosterone and to be resistant to 5 alpha-reduction. For sustained delivery of MENT, we used a system consisting of ethylene vinyl acetate implants containing MENT acetate (Ac), administered subdermally. Thirty-five normal volunteers were recruited in 3 clinics and were randomly assigned to 1 of 3 doses: 1 (12 men), 2 (11 men), or 4 (12 men) MENT Ac implants. The initial average in vitro release rate of MENT Ac from each implant was approximately 400 micro g/day. Implants were inserted subdermally in the medial aspect of the upper arm under local anesthesia. The duration of treatment was initially designed to be 6 months. However, in 2 clinics the duration of treatment was extended to 9 months for the 2-implant group and to 12 months for the 4-implant group. Dose-related increases in serum MENT levels and decreases in testosterone, LH, and FSH levels were observed. Effects on sperm counts were also dose related. None of the subjects in the 1-implant group exhibited oligozoospermia (sperm count, <3 million/ml). Four subjects in the 2-implant group became oligozoospermic, 2 of whom reached azoospermia. Eight subjects in the 4-implant group reached azoospermia, with 1 exhibiting oligozoospermia, whereas 2 were nonresponders. Side effects generally seen with androgen administration, such as increases in erythrocyte count, hematocrit, and hemoglobin and a decrease in SHBG, were also seen in this study and were reversible. Changes in lipid parameters were moderate and transient. Liver enzymes showed small changes. This study demonstrates that MENT Ac, when administered in a sustained release fashion via subdermal implants, can inhibit spermatogenesis over a prolonged period after a single administration and has the potential to be used as a male contraceptive.
von Eckardstein
Sigrid
S
Institute of Reproductive Medicine, University of Munster, Munster, Germany.
Noe
Gabriela
G
Brache
Vivian
V
Nieschlag
Eberhard
E
Croxatto
Horacio
H
Alvarez
Francisco
F
Moo-Young
Alfred
A
Sivin
Irving
I
Kumar
Narender
N
Small
Margaret
M
Sundaram
Kalyan
K
D000328:Adult; D003272:Contraceptive Agents, Male / Q000008:administration & dosage* / Q000009:adverse effects; D004343:Drug Implants; D004542:Ejaculation / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000097:blood; D006400:Hematocrit; D006454:Hemoglobins; D006801:Humans; D008055:Lipids / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D009277:Nandrolone / Q000008:administration & dosage* / Q000009:adverse effects; D010410:Penile Erection / Q000187:drug effects; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D013076:Sperm Count; D013091:Spermatogenesis / Q000187:drug effects; D013739:Testosterone / Q000097:blood
D003272:Contraceptive Agents, Male; D004343:Drug Implants; D006454:Hemoglobins; D008055:Lipids; D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D009277:Nandrolone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone